Start: January 31, 2019
End: June 30, 2024
Enrollment: 88
This study will test the effects of memantine on brain function and dementia symptoms in older adults with mild to moderate Alzheimer's disease who are not currently taking Alzheimer's medications. Memantine, also known as Namenda, is a drug approved by the U.S. Food and Drug Administration to treat moderate to severe symptoms of Alzheimer's disease. In this study participants will be randomly assigned to take either memantine (20 mg) or a placebo twice daily for about six weeks.
Minimum Age: 50 Years
Maximum Age: 83 Years
Contact study personnel listed either under the general study contact or the location nearest you.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
California | |
---|---|
Clinical Teaching Facility (CTF-B102) at UCSD Medical Center
San Diego, CA 92103
Recruiting
Jo Talledo, B.A. |
Lead: University of California, San Diego
Source: ClinicalTrials.gov ID: NCT03703856